Genta Clinical Programs Featured in Presentations at Annual Meeting of the American Society of Hematology

BERKELEY HEIGHTS, N.J., Dec. 4 /PRNewswire-FirstCall/ -- Genta Incorporated (NASDAQ: GNTA) announced that several presentations related to the Company's clinical programs will be featured at the annual meeting of the American Society of Hematology (ASH) in Orlando, FL during December 9-12, 2006. Programs involving Genasense(R) (oblimersen sodium) Injection, Genta's lead anticancer compound, are featured in several abstracts related to chronic lymphocytic leukemia (CLL), as follows:

  - Durable clinical benefit is associated with objective response and not
    lack of progression in patients with relapsed/refractory chronic
    lymphocytic leukemia (CLL): Results from the Genasense/Flu/Cy Phase 3
    Study. Poster #57-III; Monday, December 11, 2006, 10:30 am-7:00 pm.

  - "Complete" remission in chronic lymphocytic leukemia (CLL) is strongly
    affected by the use of CT Scanning: Results from a prospective
    randomized trial of fludarabine plus cyclophosphamide (Flu/Cy) with or
    without Genasense (oblimersen) in patients with relapsed or refractory
    disease. Poster #63-III; Monday, December 11, 2006, 10:30 am-7:00 pm.

Text of these abstracts can be viewed at the ASH website: http://www.hematology.org/. Scientific and clinical aspects of apoptotic defects in CLL and potential new therapeutic options that target apoptosis will be discussed in a scientific symposium on Friday, December 8th. That session, entitled "Targeting Apoptosis: The Next Generation of Cancer Therapy", includes the following presentations and speakers:

  - Clinical Results: Targeting Apoptosis in CLL:  Bruce D. Cheson, MD,
    Professor of Medicine and Head of Hematology, Georgetown University
    Hospital, Lombardi Comprehensive Cancer Center.

  - Why Target Apoptosis?:  Dennis A. Carson, MD, Professor of Medicine,
    University of California, San Diego, and Director, USD-Moores Cancer
    Center.

  - New Technologies: The Road to Individualized Therapy:  Anthony G. Letai,
    MD, PhD, Assistant Professor of Medicine, Harvard Medical School,
    Department of Medical Oncology/Hemtaologic Neoplasia, Dana-Farber Cancer
    Institute.

  - Apoptosis Activation: Clinical Lessons Learned:  Anthony W. Tolcher, MD,
    Director of Clinical Research, Institute for Drug Development, Cancer
    Therapy & Research Center, San Antonio, TX.

  - Apoptosis Targeted Therapy: Where Are We Going?:  Owen A. O'Connor, MD,
    PhD, Attending Physician and Head, Laboratory of Experimental
    Therapeutics for Lymphoproliferative Malignancies, and Member, Lymphoma
    Service, Memorial Sloan-Kettering Cancer Center, New York, NY.

  About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the company's lead compound from its oligonucleotide program. The Company has submitted a New Drug Application (NDA) to the Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com/.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

  - the company's ability to obtain necessary regulatory approval for
    Genasense(R) from the U.S. Food and Drug Administration ("FDA") or
    European Medicines Agency ("EMEA");
  - the safety and efficacy of the company's products or product candidates;
  - the company's assessment of its clinical trials;
  - the commencement and completion of clinical trials;
  - the company's ability to develop, manufacture, license and sell its
    products or product candidates;
  - the company's ability to enter into and successfully execute license and
    collaborative agreements, if any;
  - the adequacy of the company's capital resources and cash flow
    projections, and the company's ability to obtain sufficient financing to
    maintain the company's planned operations;
  - the adequacy of the company's patents and proprietary rights;
  - the impact of litigation that has been brought against the company and
    its officers and directors;
  - the Company's ability to regain compliance with the NASDAQ's listing
    qualifications; and
  - the other risks described under Certain Risks and Uncertainties Related
    to the company's Business, as contained in the company's Annual Report
    on Form 10-K and Quarterly Report on Form 10-Q.

The company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the company's Annual Report on Form 10-K for 2005 and its most recent quarterly report on Form 10-Q.

  SOURCE: Genta Incorporated

  CONTACT:
  Tara Spiess/Andrea Romstad
  TS Communications Group, LLC
  info@genta.com
  (908) 286-3980